


[Sar9,Met(O2)11]-Substance P TFA

Cat. No.:	HY-P1012A
CAS No.:	2828433-10-7
Molecular Formula:	C ₆₆ H ₁₀₁ F ₃ N ₁₈ O ₁₇ S
Molecular Weight:	1507.68
Sequence:	Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-{Sar}-Leu-Met[O2]-NH2
Sequence Shortening:	RPKPQQFF-{Sar}-LM[O2]-NH2
Target:	Neurokinin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Sealed storage, away from moisture
	Powder -80°C 2 years
	-20°C 1 year



* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (66.33 mM); Need ultrasonic				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	0.6633 mL	3.3164 mL	6.6327 mL
		5 mM	0.1327 mL	0.6633 mL	1.3265 mL
10 mM		0.0663 mL	0.3316 mL	0.6633 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 50 mg/mL (33.16 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	[Sar9,Met(O2)11]-Substance P TFA is a tachykinin NK ₁ receptor selective agonist.
IC₅₀ & Target	NK ₁ receptor ^[1]
In Vitro	[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cellier E, et al. Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat. Br J Pharmacol. 1999 Jun;127(3):717-28.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA